Emerging Microbes and Infections (Jan 2020)

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

  • Danielle E. Anderson,
  • Chee Wah Tan,
  • Wan Ni Chia,
  • Barnaby E. Young,
  • Martin Linster,
  • JennyG. H. Low,
  • Yee-Joo Tan,
  • Mark I.-C. Chen,
  • Gavin J. D. Smith,
  • Yee Sin Leo,
  • David C. Lye,
  • Lin-Fa Wang

DOI
https://doi.org/10.1080/22221751.2020.1761267
Journal volume & issue
Vol. 9, no. 1
pp. 900 – 902

Abstract

Read online

ABSTRACTDespite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.

Keywords